Nick Brandon

Chief Scientific Officer at Neumora Therapeutics, Neuroscientist, Footy/soccer dad

[Nick Brandon @NickJBrandon73]

Excited to see Neumora Therapeutics emerge - it’s been an amazing experience working alongside @carolysuh, Mike Poole, John Dunlop, John Reynders, @andrewejaffe and the rest of our amazing team to build the company

[Neumora @NeumoraTx]

We are Neumora, a clinical stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and #neuroscience. Read more about our launch here: https://t.co/VAp6qWwmRF

[Neumora @NeumoraTx]

We’ve opened the doors to our new office – a space designed to foster innovation, collaboration and connection. We’re excited to grow here and expand our work on behalf of people living with brain diseases.

Check out some photos of our team together in the new space.

[Vanderbilt CTTC @VanderbiltCTTC]

Congratulations to Neumora and the Warren Center for Neuroscience Drug Discovery team for this exciting update! Read the full press release: https://t.co/UtOlFjsYbz

[WCNDD @WCNDD_TN]

🧠 New publication alert!

WCNDD’s first-in-human study of VU0467319, a selective M1 muscarinic receptor PAM, shows it’s safe, well-tolerated, and engages its target — a promising step for Alzheimer’s disease therapeutics.

📄 Read more: https://t.co/DF7IK8DB6g

[Neumora @NeumoraTx]

Today we announced the initiation of a Phase 1 clinical study for NMRA-861, our M4 positive allosteric modulator (PAM). Read more here: https://t.co/qSfr7kZPoh

[Neumora @NeumoraTx]

April is #ParkinsonsAwarenessMonth. At Neumora, we’re dedicated to developing therapies that revolutionize care for those living with brain disease. Learn more: https://t.co/TiRK9woJH9 #WorldParkinsonsDay

[ShorterLab @ShorterLab]

Researchers Report on the Opposing Roles of p38α Phosphorylation and Protein Arginine Methyltransferase 1 (PRMT1) Methylation in TDP-43 Proteinopathy, thanks to @TargetALS_fdn for supporting our work! https://t.co/9JyrNmvLqM

[ShorterLab @ShorterLab]

Opposing roles of p38α-mediated phosphorylation and PRMT1-mediated arginine methylation in driving TDP-43 proteinopathy: Cell Reports https://t.co/KMYNEul1LY

[Neumora @NeumoraTx]

We’re nominated for the #NEVYs24 Powerhouse Life Science Company of the Year! At Neumora, our mission is to reshape the treatment of brain diseases by developing novel therapeutic options for people in need. We look forward to tomorrow’s @NewEnglandVC awards ceremony!

[Neumora @NeumoraTx]

Many people living with major depressive disorder (MDD) experience inadequate response or tolerability issues with first-line medication, significantly impacting their quality of life. Neumora's mission is to develop improved treatment options for those living with brain diseases like MDD.

[Neumora @NeumoraTx]

With the help of @Nasdaq, we commemorated our first anniversary as a public company today! Advancing novel medicines for patients living with #brainhealth disorders is our top priority, and we continue to make important strides toward this goal.

[Neumora @NeumoraTx]

We will host a virtual roundtable to discuss the neuropsychiatric treatment landscape this Thursday, 9/12. Register here to listen live. https://t.co/jhGSrTvvpR $NMRA

[ShorterLab @ShorterLab]

Molecular Visualization of Neuronal TDP43 Pathology In Situ https://t.co/xGeDxX9ZHV

[Target ALS @TargetALS_fdn]

Target ALS CEO Manish Raisinghani discusses our Seven Pillar Strategy, which is aimed at accelerating #ALSResearch. With a lean team, we've seen 60% of projects evolve into drug discovery, leading to 7 trials and 5 startups.

Learn more: https://t.co/0BBswkLt53
#ALS #Neuroscience

[Neumora @NeumoraTx]

We are advancing a leading pipeline with the potential to help millions of people with brain diseases. Watch below for more details on our pipeline.

[Parkinson's UK @ParkinsonsUK]

We're partnering with US biotech company, Neumora Therapeutics, to help accelerate the final lab-based work to advance a potential new drug targeting inflammation.

If this 2 year project is successful, the drug will be ready to move towards testing in people in clinical trials.

[Neumora @NeumoraTx]

Congratulations to Neumora Board Member Kristina Burow of @ARCHVentures on her inclusion in @STATNews' 2024 STATUS list! Kristina is an inspiring leader who has played a key role in our growth since inception. Read more from STAT: https://t.co/Zpt0vEoaSu

[ShorterLab @ShorterLab]

Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD | Science Translational Medicine https://t.co/RoGKBlJnfg

[Neumora @NeumoraTx]

It's been a great week at #JPM24! Check out CEO Henry Gosebruch’s podium presentation, outlining our industry-leading pipeline & the exciting year ahead. We look forward to continuing to lead innovation in #brainhealth throughout 2024. https://t.co/g55TAlXdH4

[Neumora @NeumoraTx]

Our pipeline is comprised of programs for neuropsychiatric disorders & neurodegenerative diseases, each targeting a novel mechanism of action. Learn more about below. #JPM24

[Neumora @NeumoraTx]

We've had a great week connecting with so many neuropsych thought leaders at #ACNP2023. Dr. Sanjay Mathew presented data from our #MDD program. Thank you for an excellent week, @ACNPorg!